Phase 2, Placebo-Controlled, Parallel Group Dose-Finding Study to Evaluate the Efficacy and Safety of Three Dose Levels of AD036 in Adults With Obstructive Sleep Apnea
Latest Information Update: 18 Jan 2023
Price :
$35 *
At a glance
- Drugs AD 036 (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- Sponsors Apnimed
- 13 Dec 2019 Status changed from active, no longer recruiting to completed.
- 31 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 22 Feb 2019 New trial record